The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Northern District of California on behalf of shareholders of Revance Therapeutics, Inc. who purchased shares between November 25, 2019 and October 11, 2021.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that:
(i) quality control deficiencies existed at the Company’s manufacturing facility for DaxibotulinumtoxinA for Injection (“DAXI”); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration (“FDA”) would approve the DAXI Biologics License Application (“BLA”) in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until February 8, 2022 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.